Simulations Plus (SLP) Acquires Immunetrics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
June 20, 2023 8:00 AM EDTAcquisition increases breadth and depth of QSP expertise and range of therapeutic applications
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (Simulations Plus), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the acquisition of Immunetrics, Inc. (Immunetrics), a modeling and simulation company focused on accelerating drug development in oncology, immunology, and autoimmune diseases, areas that are among the fastest growing therapeutics.
Under the terms of the Agreement, Simulations Plus agreed to pay the shareholders of Immunetrics cash... More
